Probucol was given to rats made diabetic by streptozotodn. Compared with diabetic rats not receiving probucol or with nondiabetic rats, probucol lowered the plasma concentrations of trigrycerkies, phospholipids, cholesterol, and apolipoproteln B. The concentrations of serum chylomicrons and very low density lipoprotein (VLDL) were also reduced. In control and diabetic rats, probucol enhanced the clearance of endogenoushy radiolabeled VLDL from the plasma. Clearances from the plasma of rat lymph chylomicrons or chylomicronlike lipkJ emulsions were slow in diabetic rats. Probucol normalized chyiomicron clearance in diabetic rats primarily by restoring hepatic uptake of remnants, which was decreased in diabetes. In diabetic rats, uptake of chyiomicron remnants was increased in a number of extrahepatic tissues, including the heart and kidney. Probucol significantly decreased uptake in some extrahepatic tissues. Increased plasma clearance of VLDL and chylomicrons was associated with an increase in the apolipoprotein CH/Clll and apolipoprotein E/C ratios. Orally administered probucol was specifically incorporated into lymph chylomicrons, and clearance of probucol from the plasma exactly paralleled the clearance of chyiomicron remnants, as traced with radiolabeled cholesteiyl esters. Chylomicron-like emulsions incorporating probucol were exclusively cleared from the plasma by the liver in normal rats. We conclude that in streptozotodn diabetic rats, probucol is an effective hypolipidemic agent because it promotes the clearance of the trigiyceride-rich lipoproteins. are frequently found in patients with diabetes mellitus. The hyperlipidemia primarily reflects slow clearance of plasma lipoproteins, although overproduction of lipoproteins may also be a contributing factor in non-insulin-dependent diabetes.
H ypertriglyceridemia and hypercholesterolemia
are frequently found in patients with diabetes mellitus. The hyperlipidemia primarily reflects slow clearance of plasma lipoproteins, although overproduction of lipoproteins may also be a contributing factor in non-insulin-dependent diabetes. 1 A defective clearance from the plasma of chylomicrons and very low density lipoproteins (VLDLs) has been reported in human diabetic patients (for a review, see Howard 1 ) and in animal models of this disease. 2 " 4 Hydrolysis of triglycerides may be compromised by severe insulin deficiency because insulin maintains the synthesis and secretion of lipoprotein lipase in some tissues. 5 Posthydrolysis clearance of the remnant particles is also delayed, 6 although the reasons for this are unclear. Elevated plasma concentrations of triglycerides and cholesterol are thought to contribute to the high incidence of atherosclerosis in diabetic patients, and so it is desirable to reduce the concentrations of these lipids.
Probucol is a potent hypolipidemic agent that reduces serum cholesterol level principally by increasing the fractional catabolic rate of low density lipoprotein (LDL). 7 ? Probucol is an effective lipid antioxidant, but it is not clear whether its pharmacological actions on the metabolism of LDL are related to the prevention of oxidation. Lipoproteins from diabetic donors show increased amounts of oxidative products compared with lipoproteins of nondiabetic origin. Probucol has been shown to decrease oxidation of LDL and VLDL in streptozotocin diabetic rats and in VLDL from nephrotic rats. 9 - 10 In this study we report the effects of probucol on the clearance from plasma and on organ uptake of triglyceride-rich lipoproteins in normal and diabetic rats.
Methods
Male Wistar rats (body weight, 220-250 g) were allowed free access to standard crushed rat chow and water. Rats were made diabetic with streptozotocin injected into a tail vein (55 mg/kg body wt in citrate buffer, pH 4.0). Diabetic rats were hyperglycemic, showed glucosuria, and had a low concentration of plasma immunoreactive insulin (IRI). Two weeks after streptozotocin injection, some diabetic rats were given chow containing 1% (wt/wt) probucol for either 3 weeks or 10 days. Diabetic rats failed to gain weight at the same r$te as control animals (252±15 and 291 ±3.0 g, respectively, p< 0.025), and probucol had no affect on body weight (256±9.1 g in the diabetic group receiving probucol and 293 ±7.3 g in the control group given probucol). Fasted animals were deprived of food for 16-18 hours before experimentation. All experimental procedures with rats were approved by the Senate of Western Australia through The Animal Welfare Committee.
Isolation and Radiolabeling of VLDL
Blood was collected from the abdominal aorta of anesthetized rats (pentobarbitone, 65 mg/kg body wt). EDTA (1 mM) was used to prevent coagulation of blood. Plasma was separated by low-speed centrifugation at 4°C. The plasma fraction containing chylomicrons and VLDL was isolated by ultracentrifugation at a density of 1.006 g/ml at 108,000g for 18 hours at 20°C. For radiolabeled VLDL, donor rats were injected with 100 ^tCi [9,10(n)- 3 H]oleic acid complexed to albumin and bled 45 minutes later. We have previously shown that the triglyceride fraction contains >98% of the radioactivity.
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Isolation of Rat Lymph Chylomicrons
Triolein that contained [ ]-cholesterol were given to rats by way of a gastric tube. The radiolabeled palmitic acid and cholesterol are primarily incorporated into chylomicron triglycerides and cholesteryl esters, respectively. Lymph was collected via a polyvinyl cannula placed in the mesenteric lymph duct into tubes containing EDTA (5 mM). Lymph was removed from the cells by centrifugation at 3,000 rpm for 10 minutes. Chylomicrons were isolated by density gradient ultracentrifugation as previously described. 12 In some experiments, radiolabeled probucol and cholesterol dissolved in triolein were given to the rats, and the lymph was collected.
Injection Studies With Endogenousfy Radiolabeled VLDL Triglyceride
VLDL triglyceride kinetics were determined in pentobarbital sodium-anesthetized rats by injecting radiolabeled VLDL triglyceride into the femoral vein of recipients and monitoring the decline in triglyceridespecific radioactivity. The mass of VLDL triglyceride injected was <5% of the recipient's total plasma triglyceride pool. Blood samples (400 fil) were drawn from a polyethylene cannula (PE-50, 0.58-mm i.d.) in the opposite femoral vein at 1-2-minute intervals for up to 14 minutes. After each sample withdrawal, the cannula was flushed with an equivalent volume of 0.15 M NaCl. Plasma was collected after centrifugation at 3,000 rpm for 10 minutes. Radioactivity in 200 /xl plasma was counted in 5 ml of scintillation fluid.
Preparation of Chylomicron-like Lipid Emulsion Particles
Lipid emulsions resembling the triglyceride-rich lipoproteins in composition and size were prepared as previously described. 13 Briefly, [ 
Injection Studies With Radiolabeled Chylomicrons and Chylomicron-like Lipid Particles
Control rats were anesthetized with diethyl ether and cannulated in the left carotid artery and the left jugular vein. The rats were allowed to recover from the effects of anesthesia for 3-4 hours. Doubly labeled lymph chylomicrons or a chylomicron-like emulsion (approximately 0.25 mg triglyceride in 0.4 ml) was injected by way of the jugular vein. Seven blood samples of 0.4 ml each were taken from the carotid artery at regular intervals within a 30-minute period. After each sample withdrawal, an equivalent volume of physiological saline was injected. Animals were killed immediately after the final blood sample was taken with a lethal dose of pentobarbitone given intravenously. Organs and tissues were excised, weighed, and washed briefly in physiological saline. Samples of tissues were extracted according to the method of Folch et al, 14 except that 0.03 M HC1 replaced the water added to the solvent phase. After filtration and phase separation, an aliquot of the solvent phase was dried and radioactivity determined. Plasma and tissue radioactivities were measured in a Beckman liquid scintillation counter (model LS38OO) set in duallabel mode and with auto-quench correction. Total organ uptake was calculated by correcting for the sample of tissue as the percentage of total organ weight. Total body fat was calculated as 0.078 of body weight, muscle as 0.42 of body weight, and bone marrow as 0.30 of body weight.
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Apolipoprotein Analysis
Chylomicrons and VLDLs were delipidated according to the method of Herbert et al 17 and the soluble apolipoproteins separated by isoelectric focusing in polyacrylamide gels as previously described. 11 Apolipoproteins were stained with a Coomassie R250/Coomassie G250 mixture (0.01% and 0.04% by weight, respectively, in 3.5% perchloric acid). The apolipoproteins were quantified as peak area percentages of total apolipoprotein absorbance after densitometric scanning at 600 nm (Bio-Rad model 620, Bio-Rad Australia).
Lipoprotein Lipid Analysis
Plasma and lipoprotein triglycerides were measured with a commercially available test kit that corrected for free glycerol (Boehringer Mannheim, Mannheim, FRG). Cholesterol, phospholipid, and fatty acid contents were determined by commercial test kits (Wako Chemicals, Osaka, Japan). Apolipoprotein B was determined by radioimmunoassay with rabbit anti-rat apolipoprotein B. 18 
Statistical Analysis
Lipoprotein clearance data, organ uptake, and apolipoprotein profiles were evaluated by one-way analysis of variance. Probability values less than 0.05 were accepted as significant.
Results
The effect of probucol on plasma lipids in normal and diabetic rats is shown in Table 1 . In the fed state the plasma cholesterol level was significantly lower in con- •Significantly different versus untreated group.
trol rats and diabetic rats receiving probucol compared with those not receiving probucol. No difference in cholesterol concentration was seen between control rats in the fasted state. Probucol reduced the plasma concentration of triglycerides in control and diabetic rats in either the fed or fasted state. The diabetic rats were not as hyperlipidemic as we have previously reported 19 because a lower dose of streptozotocin was used. This was done to avoid severe ketoacidosis and prevent significant deterioration of physiological condition. Nevertheless, phospholipid and apolipoprotein B concentrations were greater in diabetic rats than in control rats, although this was significantly attenuated with probucol administration. Diabetic hyperlipidemia is usually reflected in the lipoproteins with a density < 1.006 g/ml (chylomicrons and VLDL). The concentrations of triglycerides and cholesterol in the chylomicron + VLDL fraction were significantly reduced by probucol in control rats. In diabetic rats the concentrations of triglycerides, cholesterol, phospholipid, and apolipoprotein B were all reduced by probucol treatment.
The clearances in control and diabetic rats of radiolabeled VLDL triglyceride are shown in Figure 1 . In each case VLDL was obtained from donor rats treated in a manner identical to the recipient animals (e.g., radiolabeled VLDL triglyceride injected into diabetic animals receiving probucol was isolated from diabetic rats receiving probucol). Clearance of VLDL triglyceride, which represents removal by lipolysis as well as particle clearance, was faster in probucol-treated normal rats than in control animals not receiving probucol. Diabetic rats had a slower clearance of VLDL triglycê ride than did control rats. However, in probucoltreated diabetic rats, clearance was markedly enhanced.
To assess whether probucol altered clearance of chylomicrons, we monitored removal of lymph chylomicrons and lipid emulsions, which resemble chylomicrons in size and composition. The clearances of chylomicronlike lipid emulsions in control and diabetic rats are shown in Figure 2 . Probucol had no affect on triolein or cholesteryl oleate clearances in control rats, the latter being indicative of particle uptake. In contrast, the slow triolein and particle clearances observed in diabetic rats were completely normalized by probucol treatment. However, probucol given for a snorter duration (i.e., 10 days) was found to only partially ameliorate the slow emulsion or chylomicron remnant clearance in diabetic rats (Figure 3) . Increased plasma clearance of emulsion lipid in diabetic rats was reflected in the organ and tissue uptake (Table 2) . Diabetic rats had less liver uptake of emulsion cholesteryl oleate compared with control rats but greater uptake by a number of extrahepatic tissues, notably the heart and kidney. Probucol significantly increased liver uptake of emulsion cholesteryl oleate and decreased uptake by the spleen, heart, and muscle. Emulsion triolein uptake was increased in the liver of diabetic rats, indicative of remnants that were relatively enriched in triglycerides. In diabetic rats, the heart and kidney were also associated with more emulsion triolein than in control rats.
Analogous to the clearance pattern of emulsions, rat lymph chylomicrons appeared to have been removed more quickly in diabetic rats given probucol for only 10 days. However, this only became evident 15 minutes after injection. Changes in organ uptake after probucol treatment were more striking (Table 3) . Like the clearance of emulsions, there was less chylomicron cholesteryl ester uptake by the liver of diabetic rats. This was completely normalized in rats that received probucol. There was also a significant increase in cholesteryl ester uptake in control rats receiving probucol. In diabetic rats, greater uptake of cholesteryl esters was seen in extrahepatic tissues, including those organs that are prone to atherosclerosis, i.e., the kidney, brain, and heart. The heart had a fourfold greater uptake in diabetic rats. Probucol significantly decreased uptake in some of the extrahepatic tissues in diabetic rats and completely restored uptake by the liver. There was also increased uptake of cholesteryl esters by adrenal and bone marrow tissues. Chylomicron triglyceride uptake mirrored that observed with the emulsions. There was increased uptake of triglycerides in the liver and heart of diabetic rats, which was not affected substantially by probucol treatment. TrigJyceride lipolysis by endothelial lipases and receptor-mediated clearance are processes regulated by apolipoproteins. Plasma VLDL and chylomicrons were isolated and the apolipoproteins separated by isoelectric gel focusing. Densitometric scanning of the apolipoproteins showed that the VLDL and chylomicrons of probucoltreated rats contained significantly more apolipoprotein E compared with "C" apolipoproteins, and there was an increase in the relative amount of apolipoprotein CII versus apolipoprotein CIII (Table 4) .
Radiolabeled probucol (a gift from Dr. Philip Ainley, Merrell Dow Pharmaceuticals, Australia) and radiolabeled cholesterol were administered as a bolus injection (in triglyceride) by way of a gastric tube to lymphcannulated rats. The amount of probucol given was 47 mg to One rat and 19 mg to another. The appearance of radioactivity in the lymph is shown in Figure 4 . Lymph was collected, and the chylomicrons were isolated by density gradient ultracentrifugation. The majority of the chylomicrons was removed from the top of the tube. Radioactivity in an aliquot of the chylomicron fraction and in an aliquot of the infranate (thoroughly mixed) was measured. Of the total lymph probucol radioactivity, 85% was recovered in the chylomicron fraction. Cholesteryl ester radioactivity was distributed as 75% in the chylomicron fraction and 25% in the pooled infranatant. The ratio of probucol to chylomicron triglycerides was approximately 0.06% (wt/wt). The probucollabeled lymph chylomicrons were injected into normal rats. Clearance of We synthesized chylomicron-like emulsions containing 3.5% of their total lipid mass as probucol. The clearance of these emulsions is shown in Figure 6 . Probucol did not influence the rate of either triolein or cholesteryl oleate clearance from the plasma. On the other hand, cholesteryl oleate radioactivity was completely recovered in the liver (105±3%) compared with only 69±3% in the rats that received emulsion without probucol.
Discussion
In hyperlipidemic patients, probucol decreases LDL cholesterol (10-20%) and high density lipoprotein cholesterol (20-30%) concentrations without significant or only modest changes in serum levels of VLDL cholesterol or triglycerides.
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- 21 In non-insulin-dependent diabetic patients, probucol significantly reduced the serum concentrations of cholesterol and triglyceride. 22 We have now found in streptozotocin-induced diabetic rats that probucol effectively reduced the plasma concentration of cholesterol and triglyceride, principally by deCTeasing the concentration of chylomicrons and VLDL. Reductions in plasma lipids were seen even in control animals receiving probucol.
Rats with streptozotocin-induced diabetes have lower or similar rates of triglyceride secretion compared with control rats. 19 Probucol does not affect triglyceride secretion rate in streptozotocin diabetic rats, 23 and so the hypolipidemic effect of probucol is probably indicative of an increased rate of clearance of lipid from the blood. We monitored the clearance of endogenously radiolabeled VLDL triglyceride in control and diabetic rats. Clearance was less rapid in diabetic rats compared with control animals, as has been previously demonstrated by others. 2 -3 However, probucol increased the efficiency of VLDL triglyceride clearance in diabetic rats such that it was not different from that in untreated control animals. Probucol also enhanced VLDL triglyceride clearance in control rats.
In previous studies, 6 -24 we excluded slow hydrolysis of VLDL triglyceride by endothelial lipases as a cause of hypertriglyceridemia in streptozotocin diabetic rats. Recently, Homma et al 25 found that probucol decreased lipoprotein lipase activity in postheparin plasma in humans while hepatic lipase activity in postheparin plasma remained unchanged. Therefore, the increased clearance rates after probucol treatment are unlikely to be due to increased hydrolysis of VLDL triglyceride.
We have established the existence of a defect in the clearance of chylomicron remnants in streptozotocin diabetic rats, 6 and it may be that probucol improved the posthydrolysis phase of the clearance of triglyceride-rich lipoprotein remnants. To assess this possibility, we monitored the clearance of rat lymph chylomicrons and chylomicron-like lipid emulsions. The latter have been clearly shown to kinetically mimic endogenous lymph chylomicrons despite the absence of apolipoprotein B48.26.27 The injected emulsion particles contain no protein and so must obtain apolipoproteins from the recipient animal for metabolism to proceed. The use of emulsion particles avoids the variability inherent in chylomicron composition from different donors and so are useful when comparing them with the endogenous lipoproteins. Yoshino ferences in the VLDLs of diabetic rats receiving probucol compared with untreated diabetic rats.
Clearance of emulsion or chylomicron triglyceride is the sum of two processes, lipolysis by endothelial lipases and particle removal, whereas clearance of cholesteryl ester represents particle clearance alone. Typically, clearance is rapid, and triglyceride is cleared more quickly than is cholesteryl ester. Chylomicron trigryceride is cleared very rapidly from the plasma in normal animals; however, in some rats receiving probucol, clearance was still enhanced. In diabetic rats we confirmed the slow clearance of chylomicron triglyceride and remnants. However, when diabetic rats were given probucol in their diet, clearance from the plasma was partially or completely normalized depending on the duration of probucol treatment. Our studies with emulsions and chylomicrons indicate that 10 days of probucol therapy was insufficient to completely restore plasma clearance, although at 3 weeks there was no difference in the clearance patterns of triglyceride or cholesteryl esters between control and diabetic rats. Perhaps of more importance than plasma kinetics is the uptake of chylomicron remnants. In diabetic rats, on average the liver only cleared about half the amount of remnants typically expected for control rats. In contrast, there was increased uptake of remnants in a number of extrahepatic tissues, notably in organs more prone to atherosclerotic lesion development, such as the heart, kidney, Time (mln) 30 and brain. Despite incomplete normalization of plasma clearance in diabetic rats after 10 days of probucol therapy, there were improvements in the pattern of organ uptake. There were no longer any differences in liver uptake between control and diabetic rats. Furthermore, tissues that in diabetic rats had increased uptake (such as the heart) were partly and in some cases completely normalized. The apolipoprotein B100/E receptor is the primary route by which chylomicron remnants are cleared in vivo. 28 Insulin stimulates the synthesis of the apolipoprotein B100/E receptor, 29 -32 and so in diabetic rats, downregulation of activity and consequently lowering of hepatic uptake of remnants would be expected. Increased uptake by the liver (and by other tissues that have significant apolipoprotein B100/E receptor activity, e.g., adrenal glands) in probucol-treated rats suggests that enhanced clearance of remnants may be due to an increase in apolipoprotein B100/E receptor activity. However, on the basis of the levels of mRNA for the apolipoprotein B100/E receptor after probucol treatment, Staels and colleagues 33 concluded that synthesis of the receptor was downregulated in control rats. Alternatively, probucol may increase the interaction between chylomicron remnants and the apolipoprotein B100/E receptor, as suggested by the exclusive uptake of emulsions containing 3.5% probucol by weight in the livers of untreated control rats. However, in addition to such a mechanism, probucol also promotes the mechanisms responsible for remnant clearance because clearance of emulsions or chylomicrons not containing probucol was also enhanced in probucol-treated rats. The plasma chylomicron and VLDL fraction of probucol-treated rats contained a greater apolipoprotein E/C ratio, which could promote binding with the apolipoprotein B100/E receptor. 34 - 35 Increased levels of apolipoprotein CII relative to apolipoprotein CM in chylomicrons and VLDL of probucol-treated rats may also promote remnant formation (and as a consequence, clearance) by promoting hydrolysis by lipoprotein lipase. McLean and Hagaman 36 have shown that probucol reduces the affinity of dimyristoylphosphatidylcholine liposomes for binding apolipoprotein CIII, a protein that inhibits interaction of remnants with the apolipoprotein B100/E receptor. 37 Whatever the biochemical mechanism for increased plasma clearance may be, it is clear that probucol promotes liver uptake of chylomicron remnants in diabetic rats.
On prolonged administration, probucol accumulates in adipose tissue. 38 Probucol's hydrophobicity suggested to us that the drug may be incorporated by intestinal mucosal cells into chylomicrons and thereafter metabolized within the plasma compartment as a chylomicron component. Our data show that in the lymph, probucol was specifically incorporated into chylomicrons. The percentage incorporated was low, consistent with poor uptake from the gastrointestinal tract. 39 Chylomicronincorporated probucol was metabolized in parallel with cholesteryl ester in normal rats. In rats, after 30 minutes the transfer of cholesteryl ester to other lipoprotein fractions is negligible, and so we conclude that probucol is metabolized with the particle per se. However, rats do not have active cholesteryl ester transfer protein activity, and it may be that probucol is transferred to other lipoprotein groups in rabbits and humans, species in which cholesteryl ester transfer protein activity is present in the plasma. Differences in cholesteryl ester transfer protein activities between species may in part determine the hypolipidemic nature of probucol.
Probucol is a potent hypolipidemic agent in diabetic rats. Probucol lowers plasma lipid levels by increasing the rate of clearance of chylomicrons and VLDL, an extension of the findings previously demonstrated for low density lipoproteins.
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8 Increased clearance of remnants appears to be primarily due to a stimulation in hepatic uptake. Greater liver uptake in probucoltreated rats primarily reflects an enhanced ability of the recipient animal to clear chylomicTons and VLDL. However, probucol that is incorporated into lipoproteins may also preferentially direct uptake of the particles by the liver.
